P e r s i s t e n c e M a r k e t R e s e a r c h
Throughout the forecast period, hospitals will retain as the dominant end-users of wound debridement products in North America. By the end of 2024, revenues procured from wound debridement products sales to hospitals will be nearly 50 % of the gross estimated revenues. ASCs and specialized clinics are expected to collectively garner over US $ 100 million in revenues by 2024-end, while wound debridement products sales accounted by North American nursing facilities will expand at a moderate CAGR of 4.6 %. Increasing incidences of chronic ulcers in North America is projected to instrument the growth in demand for wound debridement products in hospitals. Revenues generated from the wound debridement products sales in chronic ulcers treatment across North American hospitals are expected to expand at an impressive 8.2 % CAGR over the forecast period.
Download Report Table of Content, Figures, and Tables @ http:// www. persistencemarketresearch. com / market-research / north-america-wounddebridement-products-market / toc
Leading medical devices manufacturers in the US are recognized as some of the key players participating in the growth of wound debridement products market in North America. Companies such as Smith & Nephew PLC, Zimmer Biomet Holdings, Inc., Misonix, and Lohmann & Rauscher International are known for leading the market in terms of production of effective lowfrequency ultrasound wound debridement products. Derma Sciences Inc. holds an extended product portfolio for surgical wound debridement products and mechanical debridement pads, while BSN Medical specialized in traditional wound debridement and larval therapy products. Arobella Medical LLC, DeRoyal Industries Inc., and Söring GmbH are some other key manufacturers & suppliers of wound debridement products in North America.
Browse Complete Report @ http:// www. persistencemarketresearch. com / checkout / 12967
North America Wound Debridement Products Market by 2024